IJR News - today's news from every side
block
verse
w
o
rdys
billionaire
.ai
your
list
Whiteboard
App
quizie
un
school
New Journal
Loading
Genius — OpenServe
News
Home
Popular
Congress
Genius — OpenServe
Trending
AlzeCure Pharma Reports Profit and Potential $3.2B Licensing Deals
Business
— 1d
AlzeCure Pharma reported third-quarter net income of SEK 52.27 million, reversing a year-earlier loss, and nine-month net income of SEK 110.76 million. The company said two 2026 licensing agreements—with QuantumCell and Eli Lilly—have potential values of $2.2 billion and more than $1 billion, respectively, excluding royalties, and reported SEK 231.9 million in cash at quarter-end.
+3
0
Share
Lilly’s Foundayo eases sleep apnea in two trials
Business
— 5d
Eli Lilly says its obesity pill Foundayo reduced obstructive sleep apnea in two late-stage trials and plans to seek U.S. approval for the use by year-end, though results suggest it may be less effective than the company’s Zepbound injection. Other potential treatments are advancing, including Pfizer’s recruiting Phase 3 trial of a monthly injection and Incannex’s oral therapy, which showed promising results in an earlier-stage study.
+6
0
Share
Lilly Signs Multiyear Deal for Logos at Indiana, Purdue Courts
Business
— Oct 30, 2026
Eli Lilly has signed a multiyear partnership with Indiana and Purdue athletics, placing its logo on the basketball courts at Assembly Hall and Mackey Arena. The sponsorship is Lilly’s first in college athletics and will also promote the company’s career opportunities and recruiting connections with students.
+9
0
Share
Lilly Drug Shows Double Ozempic Weight Loss
Health
— Oct 28, 2026
Eli Lilly says its experimental weekly drug retatrutide produced about 20%–21% weight loss and greater blood-sugar reductions than Ozempic in an 80-week trial of adults with Type 2 diabetes. The results are company-reported, and retatrutide has not been approved; side effects led more participants on the highest dose to stop treatment than on Ozempic.
+3
0
Share
IJR
Blue State Residents Balk At NFL Owner’s $16 Billion Data Center Project That Could Cut Their Property Taxes
Simon August · 6 min · 11h
Lilly Retatrutide Meets Endpoints in Phase 3 Trials
United States Food and Drug Administration
— Jul 23, 2026
Eli Lilly announced positive Phase 3 results for retatrutide in TRIUMPH-2 and TRIUMPH-3, showing substantial weight loss and improved metabolic and cardiovascular risk markers, with average losses ranging roughly from the high 20s to the mid-50s pounds across different doses. The company plans to submit a Biologics License Application to the FDA in early 2027 as it moves toward global regulatory submissions for obesity and related conditions.
+4
0
Share
Most Influential Women in World History
Yourlist
— Ranking
From ancient queens who ruled empires to modern activists who changed laws, these women left indelible marks on politics, science, and culture. Vote for who you think shaped history most profoundly.
Share
Lilly Plans $2.88B Merida Autoimmune Acquisition
Business
— Sep 3, 2026
Eli Lilly is rapidly expanding beyond its obesity-and-diabetes blockbuster lineup, striking two multi-deal paths: a $2.875 billion-plus acquisition of Merida Biosciences to broaden its autoimmune and antibody-directed therapies, and a $3.83 billion spree to acquire three biotech firms—Curevo, LimmaTech Biologics, and Vaccine Company—to build a broader vaccine and infectious-disease pipeline. The moves underscore a strategy to diversify growth into immunology, infectious diseases, and autoantibody therapies while managing revenue risk from reliance on a small number of weight‑loss drugs.
+2
0
Share
